Only 0.2% of patients appeal insurance denials, yet 80% succeed. This article examines how even small increases in appeals could shift insurer behavior, raise costs, influence Wall Street expectations, and reshape the economics of American healthcare.

Gallup reports 82 million Americans cut back on daily life to afford healthcare. Coverage shifts financial risk to families through deductibles and prior authorization. Diagnosis now operates like a private tax on survival and forces tradeoffs across work, housing, and retirement.

Blue Cross Blue Shield says insurers protect patients from high drug prices. The real world shows delays, denials, and blame shifting while patients wait, appeal, and deteriorate. A closer look at how insurers deflect responsibility in the drug pricing debate.

The new bipartisan proposal to separate insurers, PBMs, and providers targets the financial structure behind rising costs and denials. This piece explains how ownership concentration reshaped care, why regulation failed, and what structural separation could change for patients.